Apple shares tumble 4 percent in heavy trade


NEW YORK/SAN FRANCISCO (Reuters) - Shares of Apple Inc tumbled nearly 4 percent on Wednesday, rounding off a bleak ten weeks for the most valuable U.S. company, with analysts citing factors such as increasing competition in the tablet market.


The stock was one of the biggest percentage losers on the S&P 500, dropping 5.2 percent to $545.56 at one point as more than 17 million shares changed hands, putting it on track to surpass the company's average daily volume over 50 days of 21 million shares.


The stock's massive size meant the retreat was responsible for two-thirds of the 1.1 percent decline in the Nasdaq 100 Index on Wednesday.


Analysts gave different reasons for the decline. Some cited a research report saying the company will lose share in the tablet computer space next year. Others cited reports of higher margin requirements at clearing firms, and several investors said uncertain tax rates on capital gains in 2013 prompted selling.


"Depending on what happens with the (U.S. fiscal negotiations), rates could rise next year or they could stay the same," Brian Battle, director of trading at Performance Trust Capital Partners in Chicago, said. "They will not be lower, so if you're an investor who has seen gains in Apple, it is better to take those gains this year rather than next."


Apple is still up 36 percent so far this year, but has been weak recently, dropping into bear market territory. The stock is now down nearly 22 percent from its all-time high of $705.07 a share of September 21.


Some were perplexed at the sudden falling out of favor of the stock, which so far has been a staple in almost all growth portfolios.


"Apple stock is significantly more volatile than its earnings and innovation stream," Daniel Ernst, analyst with Hudson Square Research said. "And yet the wind blows slightly from the south instead of the east one particular morning and the stock is down 6 percent."


"It makes no sense. There are lines around the block for their products all around the world," he added. "No other company has that."


On Wednesday, research firm International Data Corp said Apple would shed market share in the tablet computer space for all of 2012, with consumers favoring devices that run on Google's Android platform instead of Apple's popular iPad product line.


Apple's worldwide tablet market share would slip to 53.8 percent in 2012 from 56.3 percent in 2011, while Android products would increase their share to 42.7 percent from 39.8 percent, IDC said.


The main reason for the negative sentiment around the stock is likely concerns about new competition in the tablet market, Colin Gillis, an analyst with BGC Partners, adding that some investors who were hoping for a special dividend this year may be disappointed as time is running out.


"If you were expecting special dividend by year end, that's less likely to happen because its December 5," he said.


TAX SELLING


Separately, Nokia is to partner with China Mobile, the world's biggest mobile operator, in a sales deal that will give the Finnish company an opportunity to win back Chinese market share from Apple's iPhone.


"This is not going to be a short-term trend. This is a management test, of how well they can perform without (deceased former chief executive) Steve Jobs," said Battle.


Referring to one of Apple's most recent product launches, a version of the iPad that was smaller but not a new product category, Battle said Apple would need "another home run" for shares to return to levels around $700.


"They need another new product that hits it out of the park. Without that, they could get a gradual grind-down in confidence," he said.


The 7.9-inch iPad mini marks Apple's first foray into the smaller-tablet segment and is the company's first major new device since the death of co-founder Jobs last year.


While lines for the new iPads had appeared lighter than usual when it hit stores in November, the company said at that time that demand was so strong that it "practically sold out of iPad minis". It said it sold 3 million of its new iPads -- including the newer full-size version -- in the first three days on the market.


Apple is currently ramping up the introduction of its latest iPhone 5 smartphone and smaller iPad mini tablet in international markets. The company is launching the iPhone 5 in 50 countries in December, including China and South Korea.


Some analysts suggested that investors also sold shares of Apple amid uncertainty over ongoing fiscal negotiations in Washington. If no agreement is reached on the issue, higher taxes on dividends and capital gains are possible in 2013. That has prompted some investors to lock in profits now, particularly on a stock like Apple, which has posted gains of at least 25 percent for four consecutive years.


Tax selling "can take a life of its own," said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, New York.


"Some taxable investors take the gains, that creates some negative momentum, institutional investors are heavily weighted the stock and reduce exposure."


(Additional reporting by Charles Mikolajczak in New York and Doris Frankel in Chicago; Editing by Bernadette Baum and Andrew Hay)



Read More..

Chiefs players head to Belcher memorial service


KANSAS CITY, Mo. (AP) — Several players for the Kansas City Chiefs attended a memorial service for teammate Jovan Belcher, who killed his girlfriend and then fatally shot himself in the head.


Belcher killed 22-year-old Kasandra Perkins on Saturday at the home they shared in Kansas City with their 3-month-old daughter. He then drove to the Chiefs practice facility at Arrowhead Stadium, where he killed himself in front of team officials, who pleaded with him to put down his gun.


Retired Chiefs Hall of Famer Bobby Bell said after the private hour-long service that general manager Scott Pioli, who witnessed Belcher's suicide, spoke during the service. Bell said an uncle of Belcher also spoke.


The service was held at a church that Belcher and Perkins attended.


Several other Chiefs players declined comment after the service.


Read More..

Longer tamoxifen use cuts breast cancer deaths


Breast cancer patients taking the drug tamoxifen can cut their chances of having the disease come back or kill them if they stay on the pills for 10 years instead of five years as doctors recommend now, a major study finds.


The results could change treatment, especially for younger women. The findings are a surprise because earlier research suggested that taking the hormone-blocking drug for longer than five years didn't help and might even be harmful.


In the new study, researchers found that women who took tamoxifen for 10 years lowered their risk of a recurrence by 25 percent and of dying of breast cancer by 29 percent compared to those who took the pills for just five years.


In absolute terms, continuing on tamoxifen kept three additional women out of every 100 from dying of breast cancer within five to 14 years from when their disease was diagnosed. When added to the benefit from the first five years of use, a decade of tamoxifen can cut breast cancer mortality in half during the second decade after diagnosis, researchers estimate.


Some women balk at taking a preventive drug for so long, but for those at high risk of a recurrence, "this will be a convincer that they should continue," said Dr. Peter Ravdin, director of the breast cancer program at the UT Health Science Center in San Antonio.


He reviewed results of the study, which was being presented Wednesday at a breast cancer conference in San Antonio and published by the British medical journal Lancet.


"The result of this trial will have a major, immediate impact on premenopausal women," Ravdin said.


About 50,000 of the roughly 230,000 new cases of breast cancer in the United States each year occur in women before menopause. Most breast cancers are fueled by estrogen, and hormone blockers are known to cut the risk of recurrence in such cases.


Tamoxifen long was the top choice, but newer drugs called aromatase inhibitors — sold as Arimidex, Femara, Aromasin and in generic form — do the job with less risk of causing uterine cancer and other problems.


But the newer drugs don't work well before menopause. Even some women past menopause choose tamoxifen over the newer drugs, which cost more and have different side effects such as joint pain, bone loss and sexual problems.


The new study aimed to see whether over a very long time, longer treatment with tamoxifen could help.


Dr. Christina Davies of the University of Oxford in England and other researchers assigned 6,846 women who already had taken tamoxifen for five years to either stay on it or take dummy pills for another five years.


Researchers saw little difference in the groups five to nine years after diagnosis. But beyond that time, 15 percent of women who had stopped taking tamoxifen after five years had died of breast cancer versus 12 percent of those who took it for 10 years. Cancer had returned in 25 percent of women on the shorter treatment versus 21 percent of those treated longer.


Tamoxifen had some troubling side effects: Longer use nearly doubled the risk of endometrial cancer. But it rarely proved fatal, and there was no increased risk among premenopausal women in the study — the very group tamoxifen helps most.


"Overall the benefits of extended tamoxifen seemed to outweigh the risks substantially," Dr. Trevor Powles of the Cancer Centre London wrote in an editorial published with the study.


The study was sponsored by cancer research organizations in Britain and Europe, the United States Army, and AstraZeneca PLC, which makes Nolvadex, a brand of tamoxifen, which also is sold as a generic for 10 to 50 cents a day. Brand-name versions of the newer hormone blockers, aromatase inhibitors, are $300 or more per month, but generics are available for much less.


The results pose a quandary for breast cancer patients past menopause and those who become menopausal because of their treatment — the vast majority of cases. Previous studies found that starting on one of the newer hormone blockers led to fewer relapses than initial treatment with tamoxifen did.


Another study found that switching to one of the new drugs after five years of tamoxifen cut the risk of breast cancer recurrence nearly in half — more than what was seen in the new study of 10 years of tamoxifen.


"For postmenopausal women, the data still remain much stronger at this point for a switch to an aromatase inhibitor," said that study's leader, Dr. Paul Goss of Massachusetts General Hospital. He has been a paid speaker for a company that makes one of those drugs.


Women in his study have not been followed long enough to see whether switching cuts deaths from breast cancer, as 10 years of tamoxifen did. Results are expected in about a year.


The cancer conference is sponsored by the American Association for Cancer Research, Baylor College of Medicine and the UT Health Science Center.


___


Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP


Read More..

NBR Awards name 'Zero Dark Thirty' best film


NEW YORK (AP) — Kathryn Bigelow's "Zero Dark Thirty" continued to gather awards momentum as the National Board of Review named the Osama bin Laden hunt docudrama the best film of the year.


The board is the second notable group to name "Zero Dark Thirty" best film, following the New York Film Critics Circle. The two early awards suggest the film may be the Academy Awards frontrunner, four years after Bigelow's "The Hurt Locker" triumphed at the Oscars.


The film took three awards Wednesday from the National Board of Review, which also named Bigelow best director and Jessica Chastain, who stars as a CIA agent, best actress.


The group also gave a boost to the "Silver Linings Playbook," David O. Russell's comedic drama about a mentally unstable former teacher (Bradley Cooper) attempting to reorder his life. Cooper was named best actor and Russell was given best adapted screenplay. (Best original screenplay went to Rian Johnson for his script to the thriller "Looper.")


Leonardo DiCaprio won best supporting actor for his performance as a wealthy slave owner in Quentin Tarantino's "Django Unchained." Best supporting actress went to Ann Dowd for her performance as a fast-food manager terrorized by a prank caller in "Compliance."


The board also cited Ben Affleck, director and star of the Iran hostage crisis drama "Argo," for special achievement in filmmaking. Best ensemble went to the cast of Tom Hooper's musical adaptation of "Les Miserables." The group is also highlighting John Goodman with its "spotlight award," noting the actor's work this year in "Argo," ''Flight," ''Paranorman" and "Trouble With the Curve."


The National Board of Review, a group of film academics, students and professionals founded in 1909, is one of the first groups to announce its picks for the year's best movies. The Los Angeles Film Critics announce their choices on Sunday. The Golden Globe nominations come Dec. 13.


The National Board of Review has some pedigree in picking films that have gone on to win best picture at the Oscars, though not in recent years. Last year, it selected "Hugo," while the academy chose "The Artist." In 2010, it selected "The Social Network" while the academy chose "The King's Speech."


In addition to individual awards, the board also lists its top 10 films, in no particular order: "Zero Dark Thirty," ''Argo," ''Lincoln," ''Beasts of the Southern Wild," ''Django Unchained," ''Looper," ''Les Miserables," ''The Perks of Being a Wallflower," ''Silver Linings Playbook" and "Promised Land."


The awards will be handed out at a gala on Jan. 8 in New York at Cipriani's, to be hosted by Meredith Vieira.


___


Online:


http://www.nbrmp.org/


___


Follow Jake Coyle on Twitter at http://twitter.com/jake_coyle


Read More..

ICC lets ComEd delay smart meters until 2015









The Illinois Commerce Commission on Wednesday approved ComEd's request to delay the installation of smart meters until 2015 but said it will revisit the issue in April when the utility is scheduled to file a progress report on the program.

Under massive grid modernization legislation, ComEd was supposed to begin installing smart meters this year, but the ICC cut the funds ComEd was expecting to receive under the program and the utility said it could no longer afford to install the meters that quickly. The two sides are battling in court in a process that could take years.

An administrative law judge, as well as several consumer advocacy groups, had recommended the commission not accept the delay.

Jim Chilsen, spokesman for Citizens Utility Board, said a delay is not in the best interest of consumers. According to a ComEd commissioned analysis, the delay means consumers will miss out on approximately $187 million in savings that could come from the program over 20 years and will pay $5 million more for the smart meters. Chilsen said that CUB, which had urged the commission not to delay the program, will review the order once it becomes available and that it could seek to appeal the decision before the Illinois Appeals Court.

Other aspects of smart grid installation are under way, including "smart switches" used to automatically isolate outages and reroute power to customers. However, smart meters are the most consumer facing aspect smart grid and let the utility track on a computer what customers lack power and those who have had power restored.

Without the smart meters, customers must alert ComEd to an outage. Other parts of smart grid allow ComEd to see where the power is out in general.

The smart meters were a major component in ComEd's pitch to the state legislature for massive regulatory overhaul legislation that streamlines the rate-making processto give ComEd faster and more frequent rate hikes as it undertakes the multibillion-dollar grid modernization.

jwernau@tribune.com | Twitter @littlewern

Read More..

Hamstring strain could sideline Urlacher for season








Chicago Bears linebacker Brian Urlacher is expected to miss the next three games and possibly the rest of the regular season with a Grade 2 hamstring strain, according to two sources familiar with his injury status.

Urlacher hopes to be fully recovered for the playoffs, provided the Bears remain in good postseason standing. A return for the Dec. 30 regular-season finale against the Detroit Lions is a possibility.

The eight-time Pro Bowler strained his right hamstring on the second-to-last play of Sunday’s 23-17 overtime loss to the Seahawks.  Urlacher heard a "pop" as he chased Seahawks quarterback Russell Wilson near the sideline. It was a non-contact injury.

Urlacher declined to discuss the injury or his playing status when reached by the Tribune. He underwent an MRI on Tuesday, which confirmed the Grade 2 strain.


Urlacher has started in all 16 games in nine of the past 12 seasons.

After Sunday’s loss, a team source indicated the Bears needed to prepare to play without Urlacher "for a while." Nick Roach took over at middle linebacker for the final play of overtime as Geno Hayes slid over to Roach’s spot at strong-side linebacker.

This week’s game against the Vikings would be Roach’s fourth career start at middle linebacker. The Bears also had linebacker Dom DeCicco at Halas Hall on Tuesday and re-signed him for depth at the position.

If the playoffs started today, the 8-4 Bears would be the fifth seed against the fourth-seeded and NFC East-leading Giants (7-5) on wild-card weekend Jan. 5-6. Such a scenario would give Urlacher a month to fully recover.

The 34-year-old Urlacher’s contract expires at the end of the season, and he still has a desire to play at least two more seasons depending on his health. He entered the 2012 campaign recovering from a severe left knee injury sustained during last year’s season finale at Minnesota. Urlacher sprained his medial collateral ligament and partially sprained posterior cruciate ligament. He underwent multiples procedures to repair the damage.

General manager Phil Emery wouldn't commit to re-signing the future Hall of Famer and said any contract offers would be based on performance. Urlacher not only leads the team in tackles with 88, but he also has an interception return for a touchdown, three forced fumbles, and two fumble recoveries.

vxmcclure@tribune.com

Twitter@vxmcclure23






Read More..

Intel offers debt, shares jump on stock buyback hopes


SAN FRANCISCO (Reuters) - Intel on Tuesday launched a $6 billion debt sale to fund share buybacks and other activities, and the top chipmaker's stock rose more than 2 percent.


Intel was offering the bonds in a range of maturities from five years to 30 years, according to IFR, a Thomson Reuters unit.


Intel said in a filing it plans to use proceeds of the debt sale for general corporate purposes and for stock buybacks under its existing share authorization.


"We believe the action should likely prove prudent given low debt borrowing costs," RBC analyst Doug Freedman said of the debt offer in a note to clients. "In our view the raise will likely support increased buybacks."


Intel's stock has dropped 18 percent over the past year as investors worried about slow PC sales and the company's failure to expand into mobile gadgets.


It's shares were up 2.3 percent at $20.00 on Tuesday.


"The cost of money is relatively inexpensive and we have an excellent credit rating. It's sound financial planning," said Intel spokesman Chuck Mulloy.


(Reporting By Noel Randewich)



Read More..

Chiefs' LB mentioned other 'girlfriend' to police


KANSAS CITY, Mo. (AP) — Police say Kansas City Chiefs linebacker Jovan Belcher spent some of his final hours sleeping in his car outside the home of another woman whom he described as his "girlfriend."


Police spokesman Darin Snapp said Tuesday that the woman's apartment complex was about 10 miles from the home where Belcher shot and killed the mother of his 3-month-old daughter, 22-year-old Kasandra Perkins. Belcher then drove to Arrowhead Stadium and killed himself in front of team officials.


Snapp says the officers who found Belcher sleeping in his car around 2:50 a.m. Saturday determined that he didn't have any outstanding warrants. He says Belcher made a phone call and that a woman let him into the building a few minutes later.


Read More..

CDC says US flu season starts early, could be bad


NEW YORK (AP) — Flu season in the U.S. is off to its earliest start in nearly a decade — and it could be a bad one.


Health officials on Monday said suspected flu cases have jumped in five Southern states, and the primary strain circulating tends to make people sicker than other types. It is particularly hard on the elderly.


"It looks like it's shaping up to be a bad flu season, but only time will tell," said Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention.


The good news is that the nation seems fairly well prepared, Frieden said. More than a third of Americans have been vaccinated, and the vaccine formulated for this year is well-matched to the strains of the virus seen so far, CDC officials said.


Higher-than-normal reports of flu have come in from Alabama, Louisiana, Mississippi, Tennessee and Texas. An uptick like this usually doesn't happen until after Christmas. Flu-related hospitalizations are also rising earlier than usual, and there have already been two deaths in children.


Hospitals and urgent care centers in northern Alabama have been bustling. "Fortunately, the cases have been relatively mild," said Dr. Henry Wang, an emergency medicine physician at the University of Alabama at Birmingham.


Parts of Georgia have seen a boom in traffic, too. It's not clear why the flu is showing up so early, or how long it will stay.


"My advice is: Get the vaccine now," said Dr. James Steinberg, an Emory University infectious diseases specialist in Atlanta.


The last time a conventional flu season started this early was the winter of 2003-04, which proved to be one of the most lethal seasons in the past 35 years, with more than 48,000 deaths. The dominant type of flu back then was the same one seen this year.


One key difference between then and now: In 2003-04, the vaccine was poorly matched to the predominant flu strain. Also, there's more vaccine now, and vaccination rates have risen for the general public and for key groups such as pregnant women and health care workers.


An estimated 112 million Americans have been vaccinated so far, the CDC said. Flu vaccinations are recommended for everyone 6 months or older.


On average, about 24,000 Americans die each flu season, according to the CDC.


Flu usually peaks in midwinter. Symptoms can include fever, cough, runny nose, head and body aches and fatigue. Some people also suffer vomiting and diarrhea, and some develop pneumonia or other severe complications.


A strain of swine flu that hit in 2009 caused a wave of cases in the spring and then again in the early fall. But that was considered a unique type of flu, distinct from the conventional strains that circulate every year.


__


Online:


CDC: http://www.cdc.gov/flu/weekly


Read More..

Huston's "Infrared" wins Bad Sex fiction prize


LONDON (AP) — It's the prize no author wants to win.


Award-winning novelist Nancy Huston won Britain's Bad Sex in Fiction award Tuesday for her novel "Infrared," whose tale of a photographer who takes pictures of her lovers during sex proved too revealing for the judges.


The choice was announced by "Downton Abbey" actress Samantha Bond during a ceremony at the Naval & Military Club in London.


Judges of the tongue-in-cheek prize — which is run by the Literary Review magazine — said they were struck by a description of "flesh, that archaic kingdom that brings forth tears and terrors, nightmares, babies and bedazzlements," and by a long passage that builds to a climax of "undulating space."


Huston, who lives in Paris, was not on hand to collect her prize. In a statement read by her publicist, the 59-year-old author said she hoped her victory would "incite thousands of British women to take close-up photos of their lovers' bodies in all states of array and disarray."


The Canada-born Huston, who writes in both French and English, is the author of more than a dozen novels, including "Plainsong" and "Fault Lines." She has previously won France's Prix Goncourt prize and was a finalist for Britain's Orange Prize for fiction by women.


She is only the third woman to win the annual Bad Sex prize, founded in 1993 to name and shame authors of "crude, tasteless and ... redundant passages of sexual description in contemporary novels."


Some critics, however, have praised the sexual passages in "Infrared." Shirley Whiteside in the Independent on Sunday newspaper said there were "none of the lazy cliches of pornography or the purple prose of modern romantic fiction" — though she conceded the book's sex scenes were "more perfunctory than erotic."


Huston beat finalists including previous winner Tom Wolfe — for his passage in "Back to Blood" describing "his big generative jockey" — and Booker Prize-nominated Nicola Barker, whose novel "The Yips" compares a woman to "a plump Bakewell pudding."


Previous recipients of the dubious honor, usually accepted with good grace, include Sebastian Faulks, the late Norman Mailer and the late John Updike, who was awarded a Bad Sex lifetime achievement award in 2008.


___


Online: http://www.literaryreview.co.uk


Read More..